Fiona Dunbar

1.3k total citations
21 papers, 885 citations indexed

About

Fiona Dunbar is a scholar working on Clinical Psychology, Psychiatry and Mental health and Organic Chemistry. According to data from OpenAlex, Fiona Dunbar has authored 21 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Clinical Psychology, 6 papers in Psychiatry and Mental health and 4 papers in Organic Chemistry. Recurrent topics in Fiona Dunbar's work include Psychedelics and Drug Studies (4 papers), Chemical synthesis and alkaloids (4 papers) and Treatment of Major Depression (4 papers). Fiona Dunbar is often cited by papers focused on Psychedelics and Drug Studies (4 papers), Chemical synthesis and alkaloids (4 papers) and Treatment of Major Depression (4 papers). Fiona Dunbar collaborates with scholars based in United States, United Kingdom and South Africa. Fiona Dunbar's co-authors include Sarah Shea, Atilla Turgay, Isabel M. Smith, Alan Carroll, Herbert Orlik, Cynthia A. Bossie, Young Zhu, Eriene Youssef, Gahan Pandina and James Rucker and has published in prestigious journals such as American Journal of Psychiatry, PEDIATRICS and Scientific Reports.

In The Last Decade

Fiona Dunbar

18 papers receiving 834 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fiona Dunbar United States 10 516 399 220 113 99 21 885
Claudia Mehler‐Wex Germany 21 609 1.2× 143 0.4× 219 1.0× 67 0.6× 100 1.0× 50 1.1k
Randall Owen United States 15 1.2k 2.4× 828 2.1× 362 1.6× 142 1.3× 223 2.3× 29 1.6k
Liza Squires United States 17 756 1.5× 348 0.9× 161 0.7× 76 0.7× 26 0.3× 39 1.1k
Samuel W. Boellner United States 15 767 1.5× 290 0.7× 148 0.7× 118 1.0× 26 0.3× 22 1.0k
Ching‐Jui Chang Taiwan 16 426 0.8× 171 0.4× 157 0.7× 71 0.6× 85 0.9× 26 877
Seema Quraishi United Kingdom 14 1.0k 2.0× 194 0.5× 239 1.1× 98 0.9× 130 1.3× 20 1.2k
Aygün Ertuğrul Türkiye 17 573 1.1× 198 0.5× 213 1.0× 95 0.8× 30 0.3× 54 962
Alexandra B. Whitworth Austria 13 273 0.5× 110 0.3× 212 1.0× 68 0.6× 24 0.2× 17 633
Manuel Arrojo Spain 18 300 0.6× 117 0.3× 227 1.0× 84 0.7× 100 1.0× 64 821
Keith Karcher United States 17 1.2k 2.3× 138 0.3× 264 1.2× 214 1.9× 49 0.5× 27 1.5k

Countries citing papers authored by Fiona Dunbar

Since Specialization
Citations

This map shows the geographic impact of Fiona Dunbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Dunbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Dunbar more than expected).

Fields of papers citing papers by Fiona Dunbar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Dunbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Dunbar. The network helps show where Fiona Dunbar may publish in the future.

Co-authorship network of co-authors of Fiona Dunbar

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Dunbar. A scholar is included among the top collaborators of Fiona Dunbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Dunbar. Fiona Dunbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sano, Yasuyo, Elizabeth A. Wilson, Kok‐Fai Kong, et al.. (2025). Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor. Journal of Investigative Dermatology. 146(1). 214–222.e7. 1 indexed citations
2.
Dunbar, Fiona, et al.. (2025). Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults. Scientific Reports. 15(1). 38874–38874.
3.
4.
Roberts, Claire, Mathieu Seynaeve, Fiona Dunbar, et al.. (2024). Rapid antidepressant effect of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in treatment-resistant patients: a phase 2a open label study. Neuroscience Applied. 3. 104765–104765.
5.
6.
Rucker, James, Matthew Butler, Catherine Bird, et al.. (2024). Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: results from an open‐label phase Ib ascending dose study. Headache The Journal of Head and Face Pain. 64(10). 1309–1317. 3 indexed citations
7.
Acosta, Ángela, et al.. (2022). Working With Lesbian, Gay, Bisexual, and Transgender Clients: Occupational Therapy Practitioners’ Knowledge, Skills, and Attitudes. American Journal of Occupational Therapy. 76(3). 7 indexed citations
8.
Dunbar, Fiona, et al.. (2021). A narrative synthesis of research with 5-MeO-DMT. Journal of Psychopharmacology. 36(3). 273–294. 41 indexed citations
9.
Rapaport, Mark Hyman, Georges M. Gharabawi, Carla M. Canuso, et al.. (2006). Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. Neuropsychopharmacology. 31(11). 2505–2513. 104 indexed citations
10.
Pandina, Gahan, Cynthia A. Bossie, Eriene Youssef, Young Zhu, & Fiona Dunbar. (2006). Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Autism and Developmental Disorders. 37(2). 367–373. 103 indexed citations
11.
Dunbar, Fiona, Young Zhu, & H. Robert Brashear. (2006). Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clinical Therapeutics. 28(3). 365–372. 16 indexed citations
12.
Dunbar, Fiona, et al.. (2004). Growth and Sexual Maturation During Long-Term Treatment With Risperidone. American Journal of Psychiatry. 161(5). 918–920. 43 indexed citations
13.
Light, Michael J., Fiona Dunbar, & Sarah Shea. (2004). P2.104 Efficacy and safety of risperidone in the treatment of children with autistic and other pervasive developmental disorders (PDD): A randomized, double-blind, placebo controlled trial. European Neuropsychopharmacology. 14. S278–S278. 4 indexed citations
14.
Shea, Sarah, Atilla Turgay, Alan Carroll, et al.. (2004). Risperidone in the Treatment of Disruptive Behavioral Symptoms in Children With Autistic and Other Pervasive Developmental Disorders. PEDIATRICS. 114(5). e634–e641. 392 indexed citations
15.
16.
Labelle, Alain, et al.. (2001). Risperidone Treatment of Outpatients with Schizophrenia: No Evidence of Sex Differences in Treatment Response. The Canadian Journal of Psychiatry. 46(6). 534–541. 22 indexed citations
17.
Dunbar, Fiona, et al.. (1995). Potential of Loperamide Oxide in the Reduction of Ileostomy and Colostomy Output. Clinical Drug Investigation. 10(3). 158–164. 3 indexed citations
18.
Derman, Wayne, et al.. (1993). Chronic ?-blockade does not influence muscle power output during high-intensity exercise of short-duration. European Journal of Applied Physiology. 67(5). 415–419. 9 indexed citations
19.
Derman, E W, et al.. (1991). Cardiovascular, Respiratory and Metabolic Effects of Nebivolol During Maximal and Submaximal Exercise Performance. Clinical Drug Investigation. 3(S1). 33–39. 3 indexed citations
20.
Dunbar, Fiona, et al.. (1990). Fine needle cytology--is aspiration suction necessary? A study of 100 masses in various sites.. PubMed. 33(6). 809–13. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claudia Mehler‐Wex Breakdown of academic impact, for papers by Randall Owen Breakdown of academic impact, for papers by Liza Squires Breakdown of academic impact, for papers by Samuel W. Boellner Breakdown of academic impact, for papers by Ching‐Jui Chang Breakdown of academic impact, for papers by Seema Quraishi Breakdown of academic impact, for papers by Aygün Ertuğrul Breakdown of academic impact, for papers by Alexandra B. Whitworth Breakdown of academic impact, for papers by Manuel Arrojo Breakdown of academic impact, for papers by Keith Karcher
Rankless by CCL
2026